![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Innate Pharma | TG:IDD | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.012 | 0.63% | 1.906 | 1.886 | 1.926 | 1.922 | 1.892 | 1.922 | 428 | 22:50:07 |
RNS Number:4055P ID Data PLC 04 September 2003 ID Data plc ("ID Data" or the "Company") Placing On 1 August 2003, ID Data announced that it had raised an initial #2 million and that it was seeking to raise a further #1 million. ID Data is pleased to announce today that subsequent to the resolutions being passed at the Company's AGM and EGM held earlier today, that it has raised a further #1 million before expenses through the issue of secured convertible loan notes 2008 ("Loan Notes") and the issue of new ordinary shares to institutional investors. This brings the total funds raised by the Company since the 1 August 2003 to #3 million. Peter Cox, ID Data's Chief Executive Officer today commented "This is good news for ID Data and will allow us to focus on winning new business and growing the Company. I hope to have news on further developments in the near future." The fundraising comprises an issue of 13,323,077 new ordinary shares at 3.25p per share providing #0.4 million additional funds and an issue of Loan Notes for #0.6 million. ID Data is aware that the issue price of 3.25p represents a significant discount to the Company's current share price, however the fundraising was agreed in principle over the two weeks prior to this announcement and the Company has been unable to issue shares until after the resolutions at today's AGM and EGM were passed. The directors confirm that the agreed issue price was the closing mid-market share price of the Company's shares on the date prior to the date on which the investors agreed in principle to participate in this fundraising. ID Data is also pleased to welcome two new institutional stakeholders, namely Artemis Investment Management Limited who have acquired 7,692,307 new ordinary shares and #0.25 million of Loan Notes and Noble Fund Managers who have acquired 4,615,385 new ordinary shares and #0.15 million of Loan Notes. The proceeds of the issue of Loan Notes and new ordinary shares will provide additional working capital to allow expansion of the business. Following today's issue of Loan Notes, ID Data has issued in total #2.34 million of Loan Notes to date. The Company has the authority to issue Loan Notes up to #4 million at any time prior to 31 March 2004. Application has been made for the new ordinary shares, which will rank pari passu with existing ordinary shares, to be admitted to trading on the Alternative Investment Market of the London Stock Exchange. Admission will become effective and dealings are expected to commence at 8.00am on Tuesday 9 September 2003. As required by rule 15 of the AIM Rules the following information falls to be disclosed: Artemis Investment Management Limited 7,692,307 ordinary shares representing 3.59 per cent. of the Company's issued share capital. For further information please contact: ID Data plc Peter Cox, Chief Executive 01536 207 000 Email: peter.cox@id-data.co.uk Media enquiries: Bankside Peter Curtain / Heather Salmond 020 7444 4140 Email: heather.salmond@bankside.com This information is provided by RNS The company news service from the London Stock Exchange END IOEUUUMABUPWGWC
1 Year Innate Pharma Chart |
1 Month Innate Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions